Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medivation Branches Out With Phase III PARP Inhibitor From BioMarin

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal is structured with significant upfront cash at $410m, but relatively low earn-out potential for a Phase III cancer candidate. It also gives Medivation two late-stage oncology compounds beyond Xtandi; CEO David Hung outlines strategy.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register